After Reaching Milestone, Is ARGEN X NV ORDINARY SHARES NETHERLANDS (OTCMKTS:ARGNF)’s Short Interest Revealing Something?

June 18, 2018 - By Richard Conner

argenx SE (OTCMKTS:ARGNF) Logo

The stock of ARGEN X NV ORDINARY SHARES NETHERLANDS (OTCMKTS:ARGNF) registered an increase of 3.05% in short interest. ARGNF’s total short interest was 20,300 shares in June as published by FINRA. Its up 3.05% from 19,700 shares, reported previously. With 100 shares average volume, it will take short sellers 203 days to cover their ARGNF’s short positions. The short interest to ARGEN X NV ORDINARY SHARES NETHERLANDS’s float is 0.09%.

It closed at $85 lastly. It is down 0.00% since June 18, 2017 and is . It has underperformed by 12.57% the S&P500.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer. The company has market cap of $. The company's lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It currently has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: